A phase II Randomized, Open-Label, Multicenter Study Comparing CO-1.01 With Gemcitabine as First-Line Therapy in Patients with Metastatic Pancreatic Adenocarcinoma To compare the efficacy of CO-1.01 and gemcitabine in patients with metastatic pancreatic adenocarcinoma and low human equilibrative nucleoside transporter 1 (hENT1) expression.

• Country None
• organs None
• Specialty None

A Phase 1/2 Study of the Safety and Efficacy of CO-1686 in Patients with Previously Treated EGFR Non-Small Cell Lung Cancer Phase 1: To evaluate the toxicity profile of escalating doses of CO-1686 and to determine the MTD and RP2D To characterize the PK profile of CO-1686 Phase 2: To evaluate tumor response (ORR + d...

• Country None
• organs None
• Specialty None

A study to test efficacy of Rucaparib in patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer To determine investigator-assessed progression-free survival (invPFS) by RECIST Version 1.1 for rucaparib versus chemotherapy.

• Country None
• organs None
• Specialty None

A Phase 2/3 clinical study to evaluate the safety and efficacy of the study medication CO-1686 compared to erlotinib in subjects with Non-Small Cell Lung Cancer Une étude clinique de phase 2/3 pour évaluer l'innocuité et l'efficacité du CO-1686,le médicament à l'étude par rapport à l'erlotinib chezdes patients atteints d’un cancer du poumon non à petites cellules To compare the antitumor efficacy of oral single-agent CO-1686 with that of erlotinib as measured by PFS, when administered as a first-line targeted treatment to patients with EGFR-mutated, advanced/m...

• Country None
• organs None
• Specialty None

Phase 3 Study of Maintenance Rucaparib in Relapsed High-grade Ovarian Cancer Ensayo de fase 3 con Rucaparib como tratamiento de mantenimiento en pacientes con cancer de ovario de alto grado y con recaídas To evaluate progression-free survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST), as assessed by the investigator, in molecularly-defined homologous recombination defic...

• Country None
• organs None
• Specialty None